glp-1 multiple sclerosis Glucagon-like peptide-1 agonist safety and efficacy in a cohort Weight Loss with MS: GLP-1
Description
Poster Presentation
In the intervention arm, weight loss was greater in the first year than at the end of follow-up (8.6% versus 0.7% in controls at 1 year
They are prescribed for people with obesity or people who are overweight and have specific weight-related health issues, when diet and exercise alone have failed
Baseline and follow-up labs, unlimited provider visits, and medication coordination are commonly included in clinician-led telehealth programs
In trials (DURATION program), once-weekly exenatide 2 mg showed slightly more A1c reduction (~1.5% drop from baseline 8.3%) than Byetta BID (~1.0% drop) with fewer GI side effects after initial weeks ( [6] )
Every medication that produces weight loss also faces the challenge of weight regain
